Blood
Articles in this Issue
Risk of second primary malignancies in patients with chronic lymphocytic leukemia treated with zanubrutinib and acalabrutinib: A real-world data analysis
Abstract Background: Second primary malignancies (SPMs) are one of the complications in patients with chronic lymphocyti...
Blinatumomab combined with low-dose chemotherapy and TKI as first-line induction for newly diagnosed ph+ b-ALL: Improved efficacy and reduced toxicity
Abstract Introduction : Ph+ B-ALL, characterized by the BCR-ABL1 fusion gene, accounts for 20-30% of adult ALL and has historically had a po...
Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas
Abstract Introduction Detection of measurable residual disease (MRD) at end-of-treatment (EOT) using ultrasensitive circulating tumor DNA (c...
Interobserver variability in calculated 4T score in the evaluation of heparin-induced thrombocytopenia
Abstract Introduction: Heparin-induced thrombocytopenia (HIT) is a potentially fatal complication of heparin therapy, resulting in thrombocy...
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)
Abstract Background BsAbs for R/R DLBCL have diverse attributes, which may influence adherence and outcomes. This study aimed to describe pa...
Overcoming surveillance gaps: Deep learning for accurate detection and chronicity classification of hospital-acquired pulmonary embolism
Abstract Introduction: Hospital-acquired venous thromboembolism (HA-VTE) is one of the most preventable causes of in-hospital death. Accurat...
Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera
Abstract Background In polycythemia vera (PV), reduction of the JAK2 V617F allele burden is increasingly recognized as a marker of disease m...
Clonal hematopoiesis does not predict solid tumor malignancy in people living with HIV
Abstract Background: Clonal hematopoiesis (CH) is more common in people living with HIV (PLWH) than HIV-negative individuals in recent studie...
Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above
Abstract Background: The prognosis of multiple myeloma (MM) has improved considerably in recent years owing to the introduction of novel age...
Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.
Abstract Background: The applicability of allogeneic stem cell transplantation (Allo-SCT) in elderly patients is debated and remains challen...
Delta opioid receptor (DOR): A novel target for reprogramming tumor-associated macrophage (TAM) immunosuppressive phenotype to overcome acquired resistance and enhance the effectiveness of cancer immunotherapies
Abstract Studies show that opioids, both endogenous and exogenous, can affect the function of macrophages, effecting their proliferation, ph...
Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study
Abstract Background VEXAS is a recently discovered rare disease with a broad spectrum of clinical manifestations. Particularly, the disease...
Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.
Abstract Background: Patients with secondary acute myeloid leukemia (sAML) have inferior outcomes compared to de novo AML (dn-AML) when treat...
Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study
Abstract Background: Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of aggressive lymphomas, accounting for 25%–30% of n...
Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma
Abstract Introduction/background: Cytokine release syndrome (CRS) is one of the most common adverse effects of bispecific antibodies (BsAbs)...
Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma
Abstract Introduction: Enrollment in hematologic malignancy trials remains low, especially among older adults, racial and ethnic minoritized...
Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence
Abstract Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory large B-cell...
Cell-free application of Deltex1 to suppress hyperactive notch signaling in t-cell acute lymphoblastic leukemia
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy of immature T-cells. Aberrant activating muta...
CD38BiTE-secretion overcomes antigen escape in BCMA-targeted CAR T cell therapy for multiple myeloma
Abstract Background: Chimeric antigen receptor (CAR) T cell immunotherapy has revolutionized cancer treatment, providing unprecedented outco...
Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies
Abstract Introduction: All FDA-approved chimeric antigen receptor (CAR) T-cell therapies targeting CD19 (CART19) for relapsed/refractory (r/...
Bone marrow transplantation outcomes in obese vs. non-obese patients: A multicenter propensity-matched Study
Abstract Background: Bone marrow transplant is a life-saving treatment for many hematologic disorders, but the success c...
Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia
Abstract Introduction A significant proportion of patients with acute myeloid leukemia (AML) have either primary induction failure or diseas...
Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)
Abstract Introduction: CAR T-cell therapies have transformed the treatment (tx) landscape of patients (pts) with LBCL. However, more than 50...
A propensity-matched analysis of real-world outcomes comparing direct oral anticoagulants and warfarin in patients diagnosed with portal vein thrombosis
Abstract Introduction: The management of portal vein thrombosis (PVT) usually includes anticoagulation therapy, with frequently used anticoa...
Progression-free survival in patients with low health-related quality of life treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial
Abstract Introduction: Zanubrutinib, a next-generation irreversible Bruton tyrosine kinase (BTK) inhibitor, was formulated with improved sel...